Advertisement

3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors

  • D. R. Illingworth
  • E. B. Schmidt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 109)

Abstract

Delineation of the mechanisms responsible for the maintenance of cholesterol homeostasis in humans has provided a sound scientific basis for the development of drugs which act to inhibit key enzymes in the pathway of cholesterol biosynthesis. In humans, the majority of cholesterol which is transported in plasma lipoproteins is derived from de novo synthesis rather than from dietary sources (Brown and Goldstein 1986). Conversion of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) to mevalonic acid by the enzyme HMG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis and is subject to metabolic regulation. Other enzymes, including HMG-CoA synthase and squalene synthase, are also subject to metabolic regulation.

Keywords

Reductase Inhibitor Familial Hypercholesterolemia Familial Hypercholesterolemia Mevalonic Acid Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmad S (1990) Lovastatin warfarin interaction. Arch Intern Med 150:2407 Alberts AW (1988) Discovery, biochemistry, and biology of lovastatin. Am J Cardiol 62: 10J - 15JGoogle Scholar
  2. Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of apoB containing lipoproteins. Implications for the pathophysiology of apo B production. J Lipid Res 31: 567–582PubMedGoogle Scholar
  3. Arad Y, Ramakrishnan R, Ginsberg HN (1992) Effects of lovastatin therapy on very low density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia. Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41: 487–493PubMedCrossRefGoogle Scholar
  4. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80: 4124–4128PubMedCrossRefGoogle Scholar
  5. Botti RE, Triscari J, Pan HY, Zayat J (1991) Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14: 256–261PubMedCrossRefGoogle Scholar
  6. Bradford RH, Shear CS, Chremos AN (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151: 43–49PubMedCrossRefGoogle Scholar
  7. Brown G, Albers JJ, Fisher LD, Schaffer SM, Lynn JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT (1990) Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298PubMedCrossRefGoogle Scholar
  8. Brown MS, Goldstein JL (1983) Lipoprotein receptors in the liver: control signals of plasma cholesterol traffic. J Clin Invest 72: 743–747PubMedCrossRefGoogle Scholar
  9. Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232: 34–47PubMedCrossRefGoogle Scholar
  10. Cianflone KM, Bilodeau M, Davignon J, Sniderman AD (1990) Modulation of chylomicron remnant metabolism by an hepatic hydroxymethyl glutaryl CoA reductase inhibitor. Metabolism 39: 274–281PubMedCrossRefGoogle Scholar
  11. East C, Alivizatos PA, Grundy SM (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318: 47PubMedCrossRefGoogle Scholar
  12. Edward PA, Lan SF, Fogelman AM (1983) Alterations in the rate of synthesis and degradation of rat liver 3-hydroxy 3-methyl glutaryl coenzyme A reductase produced by cholestyramine and mevinolin. J Biol Chem 258: 10219–10222Google Scholar
  13. Garg A, Grundy SM (1988) Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 318:81–86’Google Scholar
  14. Germershausen JI, Hunt VM, Bostedor RJ, Bailey BJ, Karkas JD (1989) Tissue selectivity of the cholesterol lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158: 3–9CrossRefGoogle Scholar
  15. Gerson RJ, McDonald JS, Alberts AW, Carnbrust DJ, Majka JA (1989) Animal safety and toxicology of simvastatin and related hydroxymethyl glutaryl coenzyme A reductase inhibitors. Am J Med 87 Suppl 4A: 23–38Google Scholar
  16. Ghidini A, Sicherer S, Willner J (1992) Congenital abnormalities ( VATER) in baby born to mother using lovastatin. Lancet 339: 1416–1417Google Scholar
  17. Glueck CJ, Oaks N, Speirs J, Tracey T, Lang J (1992) Gemfibrozil lovastatin therapy for primary hyperlipoproteinemia. Am J Cardiol 70: 1–9PubMedCrossRefGoogle Scholar
  18. Goldberg IJ, Holleran S, Ramakrishnan R, Adams M, Palmer RH, Del RB, Goodman DS (1990) Lack of effect of lovastatin therapy on the parameters of whole body cholesterol metabolism. J Clin Invest 86: 801–808PubMedCrossRefGoogle Scholar
  19. Golper TA, Illingworth DR, Morris CD, Bennett WM (1989) Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 13: 312–320PubMedGoogle Scholar
  20. Grundy SM, Bilheimer DW (1984) Inhibition of 3-hydroxy 3-methyl glutaryl coenzyme A reductase by mevinolin in familial hypercholesterolemic heterozygous: effects on cholesterol balance. Proc Natl Acad Sci USA 81: 2538–2542PubMedCrossRefGoogle Scholar
  21. Grundy SM, Vega GL (1985) Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 26: 1464–1475PubMedGoogle Scholar
  22. Hagemenas FC, Illingworth DR (1989) Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin. Arteriosclerosis 9: 355–361PubMedCrossRefGoogle Scholar
  23. Hagemenas FC, Pappu AS, Illingworth DR (1990) The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur J Clin Invest 20: 150–157PubMedCrossRefGoogle Scholar
  24. Havel RG, Hunninghake DB, Illingworth DR et al. (1987) Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter trial. Ann Intern Med 107: 609–615PubMedGoogle Scholar
  25. Henwood JM, Heel RC (1988) Lovastatin: a preliminary review of pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs 36: 429–454PubMedCrossRefGoogle Scholar
  26. Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS (1988) Multiple crm mutations in familial hypercholesterolemia. Evidence for thirteen alleles including four deletions. J Clin Invest 81: 909–916Google Scholar
  27. Hunninghake DB, Miller VT, Palmer RH (1986) Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. JAMA 256: 2829–2835CrossRefGoogle Scholar
  28. Illingworth DR (1986) Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 40: 338–343PubMedCrossRefGoogle Scholar
  29. Illingworth DR (1991) Use and abuse of lovastatin. Endocrinologist 1: 323–330CrossRefGoogle Scholar
  30. Illingworth DR, Bacon SP (1989) Treatment of heterozygous familial hypercholes terolemia with lipid lowering drugs. Arteriosclerosis Supp11: 121–134Google Scholar
  31. Illingworth DR, O’Malley JP (1990) The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipopro teinemia. Metabolism 39: 403–409PubMedCrossRefGoogle Scholar
  32. Illingworth DR, Sexton G (1984) Hypocholesterolemic effects on mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 74: 1972–1978PubMedCrossRefGoogle Scholar
  33. Illingworth DR, Bacon SP, Larsen KK (1988) Long-term experience with HMG CoA reductase inhibitors in the therapy of hypercholesterolemia. Atheroscler Rev 18: 161–187Google Scholar
  34. Illingworth DR, Cope R, Bacon SP (1990) Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin. South Med J 83: 1053–1057PubMedCrossRefGoogle Scholar
  35. Illingworth DR, Bacon SP, Pappu AS, Sexton GJ (1992a) Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 96: 53–64PubMedCrossRefGoogle Scholar
  36. Illingworth DR, Vakar F, Mahley RW, Weisgraber KH (1992b) Hypocholesterolemic effects of lovastatin in familial defective apolipoprotein B100. Lancet 339: 598–600PubMedCrossRefGoogle Scholar
  37. Jones PH, Farmer JA, Crestman MD et al. (1991) Once daily pravastatin in patients with primary hypercholesterolemia. A dose response study. Clin Cardiol 14: 146–151Google Scholar
  38. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007–3012PubMedCrossRefGoogle Scholar
  39. Kasiske BL, Tortorice KL, Heim-Duthoy KL (1990) Lovastatin treatment of hyper- cholesterolemia in renal transplant recipients. Transplantation 49: 95–100PubMedCrossRefGoogle Scholar
  40. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989) HMG CoA reductase inhibitors lower LDL cholesterol without reducing LPa levels. Circulation 80: 131–139CrossRefGoogle Scholar
  41. Ma PTS, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS (1986) Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83: 8370–8374PubMedCrossRefGoogle Scholar
  42. Mabuchi H, Haba T, Tatami R (1981) Effects of an inhibitor of 3-hydroxy-3methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 305: 478–482PubMedCrossRefGoogle Scholar
  43. Mantell G, Berg T, Staggers K (1990) Extended clinical safety profile of lovastatin. Am J Cardiol 66: 11B - 15BPubMedCrossRefGoogle Scholar
  44. Marais G, Larsen K (1990) Rhabdomyolysis and acute renal failure induced by combination and gemfibrozil. Ann Intern Med 112: 228–229PubMedGoogle Scholar
  45. McTavish D, Sorkin EM (1991) Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 42: 65–89Google Scholar
  46. Mol MJTM, Erkelens DW, Gevers-Leuven JA et al. (1986) The effects of synvinolin (MK733) on plasma lipids in familial hypercholesterolemia. Lancet 2: 936–939PubMedCrossRefGoogle Scholar
  47. Mol MJTM, Erkelens DW, Gevers-Leuven JA, Schouten JA, Stalenhoef AFH (1988a) Simvastatin (MK733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis 69: 131–137PubMedCrossRefGoogle Scholar
  48. Mol MJTM, Stuyt PMH, Stalenhoef AFH, Vant Laar A (1989b) Cholesterol synthesis inhibitors in hyperlipidemia. Lancet 1: 597Google Scholar
  49. Norman DJ, Illingworth DR, Munson J, Hosenpud J (1988) Myolysis and acute renal failure in a heart transplant recipient receiving lovastatin. N Engl J Med 318: 47CrossRefGoogle Scholar
  50. Ojala JP, Helve E, Karjalainen K, Tarkkanen A, Tikkanen MJ (1990) Long-term maintenance of therapeutic response to lovastatin in patients with familial and nonfamilial hypercholesterolemia. A three year follow-up. Atherosclerosis 82: 85–95Google Scholar
  51. O’Malley JP, Illingworth DR (1990) The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 39: 150–154Google Scholar
  52. Pappu AS, Illingworth DR, Bacon SP (1988) Reduction in plasma low density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism 38: 542–549CrossRefGoogle Scholar
  53. Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin gemfibrozil combination therapy. JAMA 264: 71–75PubMedCrossRefGoogle Scholar
  54. Prihoda JS, Pappu AS, Smith FE, Illingworth DR (1991) The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab 72: 567–574PubMedCrossRefGoogle Scholar
  55. Reihner E, Rudlang M, Stahlburg D, Bergland L, Ewerth S, Bjorkhem I, Einarsson K, Angelin B (1990) Influence of pravastatin, a specific inhibitor of HMG CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 323: 224–228PubMedCrossRefGoogle Scholar
  56. Smith PF, Eydolloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vuias KP, Kari PH, McDonald JS (1991) HMG CoA reductase inhibitors induced myopathy in the rat. Cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 257: 1225–1235Google Scholar
  57. Stalenhoef AFH, Mol MJTM, Stuyt BMJ (1989) Efficacy and tolerability of simvastatin (MK733). Am J Med 87 Suppl 4A: 39S - 43SGoogle Scholar
  58. Tikkanen MJ, Helve E, Jaattala A (1988) The Finish lovastatin study group comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Am J Cardiol 62: 35J - 43JPubMedCrossRefGoogle Scholar
  59. Tikkanen MJ, Bocanegra TS, Walker JF, Cook T (1989) Comparison of low dose of simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. Am J Med 87 Suppl 4A: 47S - 53SGoogle Scholar
  60. Tobert JA (1988) Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 28J - 34JPubMedCrossRefGoogle Scholar
  61. Todd PA, Goa KL (1990) Simvastatin. A review of pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 40: 583–607Google Scholar
  62. Tsujita Y, Kuroda M, Shimada Y (1986) CS514, a competitive inhibitor of 3hydroxy-3-methylglutaryl coenzyme A reductase: tissue selective inhibition of sterol synthesis and hypolipidemic effect in various animal species. Biochim Biophys Acta 877: 50–60PubMedGoogle Scholar
  63. Uauy R, Vega GL, Grundy SM, Bilheimer DW (1988) Lovastatin therapy in receptor negative homozygous familial hypercholesterolemia. Lack of effect on low density lipoprotein concentrations or turnover. J Pediatr 113: 387–392Google Scholar
  64. Vega GL, Grundy SM (1989) Comparison of lovastatin and gemfibrozil in normal lipidemic patients with hypoalphalipoproteinemia. JAMA 262: 3148–3154PubMedCrossRefGoogle Scholar
  65. Vega GL, Grundy SM (1990) Primary hypertriglyceridemia with border line high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil versus lovastatin therapy. JAMA 264: 2759–2765Google Scholar
  66. Vega GL, East C, Grundy SM (1988) Lovastatin therapy in familial dysbetalipoproteinemia. Effects on kinetics of apolipoprotein B. Atherosclerosis 70: 131–143PubMedCrossRefGoogle Scholar
  67. Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolemia. Changes in metabolism of apolipoprotein B containing lipoproteins. J Intern Med 227: 81–94Google Scholar
  68. Wiklund O, Angelin B, Fager G (1990) Treatment of familial hypercholesterolemia. A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apoprotein levels. J Intern Med 228: 241–247Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • D. R. Illingworth
  • E. B. Schmidt

There are no affiliations available

Personalised recommendations